LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 11, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that for the period of March 12, 2014 to September 11, 2014 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp is Scheduled to Present at the Barclays Capital 2014 Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 4, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that David P. King , Chairman and Chief Executive Officer, is scheduled to speak at the Barclays Capital 2014 Global Healthcare Conference in Miami Beach, FL.

LabCorp Announces the Availability of Thermo Scientific ImmunoCAP™ Allergy Testing Products

BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 24, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the availability of Thermo Scientific ImmunoCAP™ allergy testing products from Thermo Fisher Scientific, Inc. (NYSE: TMO).

Laboratory Corporation of America® Holdings Announces 2013 Fourth Quarter and Full Year Results and Provides 2014 Guidance

GAAP Diluted EPS of $1.43 and $6.25 for the Quarter and the Year, respectively Non-GAAP Adjusted EPS Excluding Amortization of $1.61 and $6.95 for the Quarter and the Year, respectively (negative impact from weather was $0.03 and $0.07 , respectively) 2013 Operating Cash Flow of $818.7 Million and

LabCorp to Offer New FDA approved Breast Cancer Prognostic Test

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 13, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the launch of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay, an FDA approved breast cancer prognostic gene signature assay developed by NanoString

LabCorp is Scheduled to Present at the 32nd Annual J.P. Morgan Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 6, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that David P. King , Chairman and Chief Executive Officer, is scheduled to speak at the 32 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 2, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Updates 2013 Guidance and Provides Preliminary 2014 Guidance

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 10, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today reaffirmed its prior revenue growth guidance of approximately 3% and updated its non-GAAP full year 2013 Adjusted Earnings Per Share (EPS) Excluding Amortization guidance

LabCorp to Offer the IntelliGENTM Multi-Gene Oncology Panel on the Next Generation Sequencing Platform

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 9, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the launch of a new oncology panel on its next generation sequencing (NGS) platform. The IntelliGEN assay improves sensitivity and detection rates for somatic

LabCorp Announces the Availability of Hepatitis C Virus Q80k Polymorphism Screening for the Newly Approved Drug OLYSIO™ (simeprevir)

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 3, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the immediate availability of an enhanced version of its HCV GenoSure ® NS3/4, a drug resistance test that screens for the Q80K polymorphism.